{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:15:16Z","timestamp":1792278916182,"version":"4.4.0"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T00:00:00Z","timestamp":1130371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002<jats:italic>Helicobacter pylori<\/jats:italic> eradication is a challenge in patients allergic to penicillin, especially those who have failed a first\u2010eradication trial.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To assess the efficacy and tolerability of <jats:italic>H. pylori<\/jats:italic> first\u2010line treatment and rescue options in patients allergic to penicillin.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002Prospective single centre study including 40 consecutive treatments administered to patients allergic to penicillin. Therapy regimens: First\u2010line (12 patients) omeprazole, clarithromycin and metronidazole for 7\u2003days; second\u2010line (17 patients) ranitidine bismuth citrate, tetracycline and metronidazole for 7\u2003days; third\u2010line (nine patients) rifabutin, clarithromycin and omeprazole for 10\u2003days; and fourth\u2010line (two patients) levofloxacin, clarithromycin and omeprazole for 10\u2003days. Outcome variable: a negative <jats:sup>13<\/jats:sup>C\u2010urea breath test 8\u2003weeks after completion of treatment.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Per\u2010protocol\/intention\u2010to\u2010treat eradication rates were: first\u2010line (64\/58%); second\u2010line (ranitidine bismuth citrate; 53\/47%); third\u2010line (rifabutin; 17\/11%) and fourth\u2010line regimen (levofloxacin; 100\/100%). Compliance with treatment was generally good, except with the rifabutin\u2010based regimen, which presented adverse effects in 89% of the patients, including four cases of myelotoxicity.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold> :\u2002<jats:italic>H. pylori<\/jats:italic>\u2010infected patients who are allergic to penicillin may be treated with a first\u2010line treatment combining a proton\u2010pump inhibitor, clarithromycin and metronidazole. Rescue options may include a regimen with ranitidine bismuth citrate, tetracycline and metronidazole. A levofloxacin\u2010based rescue regimen (with proton\u2010pump inhibitor and clarithromycin) may also represent an alternative, even when two or more consecutive eradication treatments have previously failed. However, rifabutin\u2003+\u2003clarithromycin\u2003+\u2003proton\u2010pump inhibitor regimen is ineffective and poorly tolerated.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02687.x","type":"journal-article","created":{"date-parts":[[2005,10,27]],"date-time":"2005-10-27T16:33:53Z","timestamp":1130430833000},"page":"1041-1046","source":"Crossref","is-referenced-by-count":55,"title":["<i>Helicobacter pylori<\/i> first\u2010line treatment and rescue options in patients allergic to penicillin"],"prefix":"10.1111","volume":"22","author":[{"given":"J. P.","family":"GISBERT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"GISBERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"MARCOS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"OLIVARES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"PAJARES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,10,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01276.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7226.31"},{"issue":"3","key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00394.x","article-title":"Treatment of Helicobacter pylori: an overview","volume":"14","author":"Axon AT","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01169.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1157\/13078424"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1083-4389.2004.00195.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00844.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(01)71738-1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957060-00006"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01173.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.022111"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-1-7"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02465.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2005.00307.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00555.x"},{"key":"e_1_2_6_17_2","first-page":"448","article-title":"The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate\u2010 vs. omeprazole\u2010based one\u2010week triple therapies in H. pylori eradication \u2013 a randomised controlled trial","volume":"114","author":"Bago J","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00580.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00486.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00081-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.2005.00324.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390116"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00719.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200010000-00007"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.00909.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2003.00128.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363240-00008"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.2.283"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.9.1301"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02522.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.6.1029"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00432-8"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00458-6"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01755.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(03)00059-8"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02622.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02687.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02687.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:44:09Z","timestamp":1697197449000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02687.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,27]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02687.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02687.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,27]]}}}